Klinische Studien (http://ClinicalTrials.gov):

1. Single-Dose Open-Label Study of XOMA 358 in Congenital Hyperinsulinism - NCT02604485
2. Open-Label Multiple-Dose Study of RZ358 in Congenital Hyperinsulinism - NCT04538989
3. A Randomized Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism - NCT04172441
4. Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism - NCT03941236
5. Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism - NCT03777176
6. Pediatric European Registry (KAMPER) - NCT01016392
7. A Non-interventional Post Authorization Study (PASS) to Evaluate Long-term Safety of Orfadin in Hypertyrosinemia Type 1 (HT-1) Patients in Standard Care - NCT02320084
   
   

EU-Grants

INEA/CEF/ICT/A2018/ 1816992 Action-No. 2018-EU-IA-0173